Fig. 2.
Fig. 2. EMSA of primitive AML cells. / Quiescent CD34+38−AML cells demonstrate NF-κB binding activity. (A) Representative example (specimen 1 in Table 1) of an EMSA shows NF-κB binding for AML CD34+/CD38−/CD123+ cells. As shown for Figure 1B, binding is competed by wild-type, but not mutant oligonucleotide, and both p50 and p65 subunits are detected. (B) Representative example of AML cells gated for CD34+/38− (left panel) and labeled by the SID method of cell-cycle analysis (right panel). An identical pattern of NF-κB binding was observed for 3 of 3 CD34+/CD38−/CD123+ AML specimens.

EMSA of primitive AML cells.

Quiescent CD34+38AML cells demonstrate NF-κB binding activity. (A) Representative example (specimen 1 in Table 1) of an EMSA shows NF-κB binding for AML CD34+/CD38/CD123+ cells. As shown for Figure 1B, binding is competed by wild-type, but not mutant oligonucleotide, and both p50 and p65 subunits are detected. (B) Representative example of AML cells gated for CD34+/38 (left panel) and labeled by the SID method of cell-cycle analysis (right panel). An identical pattern of NF-κB binding was observed for 3 of 3 CD34+/CD38/CD123+ AML specimens.

Close Modal

or Create an Account

Close Modal
Close Modal